Bimzelx (bimekizumab-bkzx)

Bimzelx is a biologic that was approved for the treatment of moderate-to-severe plaque psoriasis in 2023.

What is Bimzelx?

Bimzelx (also known by its generic name bimekizumab-bkzx) was approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Bimzelx is given by injection. For adults with plaque psoriasis, the initial dose is given at week 0 (the first week of treatment), weeks 4, 8, 12, and 16, and then every 8 weeks afterward.

To learn more, please visit the Bimzelx website.

Illustrated graphic of people around a rocket ship and computer.

Advance Online

Get the latest news on new treatment options from NPF.

Stay up to date
Two women smile and pose on a sidewalk at sunset.


The first biologic targeting IL-17A and IL-17F is now approved for adults with moderate to severe plaque psoriasis.

Read More

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2023 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.